With its fast and proven drug development process and its rich pipeline of differentiated products, Novaliq provides a unique investment opportunity for industry and financial partners.
The company is dedicated to the development of innovative pharmaceuticals based on their water-free EyeSol® technology platform. Since 2012, the sole focus of our clinical development has been ophthalmology. Novaliq has also gained experience in pulmonary drug delivery, dermatology and organ preservation.
Novaliq has successfully acquired a total capital sum of $115 million. The principal shareholder of the company is the dievini Hopp BioTech Holding GmbH & Co. KG.
Do you want further information on investment opportunities?